Seres (original) (raw)

Latest News for: seres

Edit

Seres-backed Saidou launches smart EV brand, partners with ByteDance

The Times of India 09 Jun 2026

Saidou Technology, backed by Seres Group, has launched its AIVA ...

Edit

Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend ...

Nasdaq Globe Newswire 05 Jun 2026

Agreement with Nestlé Health Science provides $25 million payable to Seres in 2026 as a buy-out of potential future VOWST™ net sales-based milestones ... .

Edit

Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going

Caledonian Record 05 Jun 2026

Agreement with Nestlé Health Science provides $25 million payable to Seres in 2026 as a buy-out of potential future VOWST™ net sales-based milestones ....

Edit

SERES THERAPEUTICS ANNOUNCES TWO TRANSACTIONS TO STRENGTHEN BALANCE SHEET, REDUCE OPERATING COSTS AND EXTEND PROJECTED OPERATING CASH RUNWAY WELL INTO THE FIRST QUARTER OF 2027 (Form 8-K) (Seres Therapeutics Inc)

Public Technologies 05 Jun 2026

SERES THERAPEUTICS ANNOUNCES TWO TRANSACTIONS TO STRENGTHEN ... Agreement with Nestlé Health Science provides $25 million payable to Seres in 2026 as a buy-out of ... CAMBRIDGE, Mass.- June 5, 2026 - Seres Therapeutics, Inc ... About Seres Therapeutics.

Edit

Management Change/Compensation (Form 8-K) (Seres Therapeutics Inc)

Public Technologies 01 Jun 2026

) Item 5.02 ... resigned from his position as a member of the board of directors of Seres Therapeutics, Inc ... Dr ... Attachments Original document Permalink. Disclaimer. Seres Therapeutics Inc.

Edit

SERES Tech Breakthroughs at 2026 WIE Drive Industry Forward

Bennington Banner 30 May 2026

Under the theme “Intelligence Moves the World, Energy ...

Edit

Notice of Proposed Sale of Securities (Form 144) (Seres Therapeutics Inc)

Public Technologies 19 May 2026

). The text version of this document is not available ... Seres Therapeutics Inc.

Edit

Statement of Changes in Beneficial Ownership (Form 4) (Seres Therapeutics Inc)

Public Technologies 19 May 2026

) FORM 4. Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue ... Washington, D.C ... Seres Therapeutics, Inc ... C/O SERES THERAPEUTICS, INC., 101 CAMBRIDGE PARK DRIVE 3 ... C/O SERES THERAPEUTICS, INC ... Seres Therapeutics Inc.

Edit

Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference

Nasdaq Globe Newswire 12 May 2026

CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Seres ...

Edit

Fundaci�n SERES impulsa una Alianza Intergeneracional para promover oportunidades con la convivencia entre generaciones

Europa Press 05 May 2026

La iniciativa aborda la convivencia de hasta seis generaciones y su impacto en el mercado laboral, el consumo y la cohesi�n social ....

Edit

Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Nasdaq Globe Newswire 05 May 2026

Clinical readout from investigator-sponsored SER-155 study in immune checkpoint inhibitor-related enterocolitis expected in the coming weeks ... .

Edit

Seres Therapeutics: Q1 Earnings Snapshot

Caledonian Record 05 May 2026

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Seres Therapeutics Inc. (MCRB) on Tuesday reported a loss of $19.9 million in its first quarter ....

Edit

SERES THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES (Form 8-K) (Seres Therapeutics Inc)

Public Technologies 05 May 2026

SERES THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND ... Seres maintains operational focus on advancing live biotherapeutic programs in inflammatory and immune diseases ... CAMBRIDGE, Mass.- May 5, 2026 -Seres Therapeutics, Inc.

Edit

Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) (Seres Therapeutics Inc)

Public Technologies 05 May 2026

The underlying data supporting these publications was developed using Seres' MbTx platform, which provides high-resolution assessment of drug pharmacology and functional mechanism of action ... Seres Therapeutics Inc.

Edit

Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation ...

Nasdaq Globe Newswire 04 May 2026

Data highlight both SER-603’s rational design that ...